Sharing Progress in Cancer Care (SPCC) shared on LinkedIn:
“Integrating biomarker-driven care into routine practice demands practical strategies for the entire multidisciplinary team.
With just ten days to go, register now for the Definitive Trial Project online course, ‘Precision Oncology in HER2-Positive Breast Cancer: From Biomarkers to Personalised Care’, broadcasting live on Monday, 28 September 2026, from 12:00 to 15:00 CEST.
Chaired by Matti Aapro and Seamus O’Reilly, this interactive three-hour session will examine how emerging evidence can directly inform everyday treatment pathways.
Our expert faculty, Paola Clauser, Marta González, Monika Gräser, Gaia Griguolo, Esther Sanfeliu, and Francesco Schettini, will address key clinical challenges including precision diagnostics, escalation and de-escalation strategies, and the integration of predictive tools such as HER2DX.
An application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
Participation is free of charge, but prior registration is mandatory.
Secure your place on OncoCorner.
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
This also can be interesting:
Premenopausal HR+/HER2 – Early Breast Cancer: Moving Beyond One-Size-Fits-All Adjuvant Therapy
